The Time Course of Irradiation Changes in Proton Beam-treated Uveal Melanomas

doi:10.1016/S0161-6420(93)31445-4

Ophthalmology

Volume 100, Issue 10, October 1993, Pages 1555-1560

https://doi.org/10.1016/S0161-6420(93)31445-4 Get rights and content

Background: Although histopathologic changes in uveal melanomas treated by irradiation have been well characterized, the timing of these effects after irradiation has not been previously evaluated.

Methods: The series consisted of a total of 92 eyes with uveal melanoma, enucleated at various intervals after proton irradiation (range, 1 month to 8 years) due to complications (n = 66) or tumor growth (n = 22), or at autopsy (n = 4). Study slides were read, using a standard protocol, by two pathologists masked to the timing of the enucleation after irradiation and the reason for the surgery.

Results: The prevalence of inflammation decreased whereas fibrosis increased with time from 15% of cases enucleated within 12 months (early cases) to 61% of those enucleated more than 30 months (late cases) after irradiation (P for trend = 0.0005). Tumor necrosis and blood vessel damage occurred early, and the prevalence of these changes was constant over time. Excluding tumors with evidence of growth after irradiation, mitotic figures became progressively less common as the interval between irradiation and enucleation increased (P for trend = 0.015); no mitotic figures were present in 40 high-power fields more than 30 months after irradiation.

Conclusion: Histopathologic changes in irradiated melanomas vary according to the time elapsed since irradiation. Inflammation decreases with time whereas fibrosis becomes more prevalent with time after irradiation. Among controlled tumors, mitotic figures appear only in recently irradiated tumors.

References (24)

ES Gragoudas et al.
Proton beam irradiation. An alternative to enucleation for intraocular melanomas
Ophthalmology
(1980)
ES Gragoudas et al.
Current results of proton beam irradiation of uveal melanomas
Ophthalmology
(1985)
MC Kincaid et al.
Complications after proton beam therapy for uveal malignant melanoma. A clinical and histopathologic study of five cases
Ophthalmology
(1988)
AW. Lawton
Proton beam therapy for uveal melanoma [letter]
Ophthalmology
(1989)
ES Gragoudas et al.
Proton beam therapy for uveal melanoma [letter]
Ophthalmology
(1989)
CL Shields et al.
Enucleation after plaque radiotherapy for posterior uveal melanoma. Histopathologic findings
Ophthalmology
(1990)
ES Gragoudas et al.
Intraocular recurrence of uveal melanoma after proton beam irradiation
Ophthalmology
(1992)
TR Vrabec et al.
Impact of local tumor relapse on patient survival after cobalt 60 plaque radiotherapy
Ophthalmology
(1991)
JM Seddon et al.
Relative survival rates after alternative therapies for uveal melanoma
Ophthalmology
(1990)
JJ Augsburger et al.
Cobalt-60 plaque radiotherapy vs enucleation for posterior uveal melanoma
Am J Ophthalmol
(1990)

KM Zinn et al.

Proton-beam irradiated epithelioid cell melanoma of the ciliary body

Ophthalmology

(1981)

AB Reese et al.

Necrosis of malignant melanoma of the choroid

Am J Ophthalmol

(1970)

Cited by (41)

Charged-particle irradiation of uveal melanoma
2012, Retina Fifth Edition
Neovascular glaucoma after stereotactic radiotherapy for juxtapapillary choroidal melanoma: Histopathologic and dosimetric findings
2011, International Journal of Radiation Oncology Biology Physics
Citation Excerpt :
Similar histopathologic features have been described with iodine 125 plaque brachytherapy (14), proton beam therapy (13), and charged-particle radiation (12). In our study the histopathology due to SRT was comparable to that described based on other methods of radiation delivery (10–15). We found a low tumor mitotic rate and a high frequency of retinal detachment, atrophy, and gliosis.
Enucleation after stereotactic radiotherapy (SRT) for juxtapapillary choroidal melanoma may be required because of tumor progression (TP) or the development of intractable radiation-induced neovascular glaucoma (NVG). We compare pathologic changes and dosimetric findings in those eyes enucleated secondary to NVG as opposed to TP to better understand potential mechanisms.
Patients with juxtapapillary choroidal melanoma treated with SRT (70 Gy in 5 fractions, alternate days over a total of 10 days) at the Princess Margaret Hospital, Toronto, Ontario, Canada, who underwent enucleation between 1998 and 2006 were selected. We correlated dosimetric data based on the patient's original SRT treatment plan with histopathologic findings in the retina, optic nerve head, and anterior chamber. A dedicated ocular pathologist reviewed each case in a blinded fashion.
Ten eyes in ten patients were enucleated after SRT. Six were enucleated secondary to NVG and four secondary to because of TP. Aggressive tumor features such as invasion of the sclera and epithelioid cell type were observed predominantly in the TP group. Retinal damage was more predominant in the NVG group, as were findings of radiation-related retinal vascular changes of fibrinoid necrosis and hyalinization. No conclusive radiation-related effects were found in the anterior chamber. The maximum point dose and dose to 0.1 cc were lower for the anterior chamber as compared with the dose to the tumor, retina, and optic nerve head. The mean 0.1-cc doses to the retina were 69.4 Gy and 73.5 Gy and to the anterior chamber were 4.9 Gy and 17.3 Gy for the NVG group and tumor progression group, respectively.
Our findings suggest that NVG is due to radiation damage to the posterior chamber of the eye rather than primary radiation damage to the anterior segment.
Charged-Particle Irradiation of Uveal Melanoma
2005, Retina: Fourth Edition
MRI of blood volume with superparamagnetic iron in choroidal melanoma treated with thermotherapy
2004, Magnetic Resonance Imaging
Functional magnetic resonance imaging (MRI) with a new intravascular contrast agent, monocrystalline iron oxide nanoparticles (MION), was applied to assess the effect of transpupillary thermotherapy in a rabbit model of choroidal melanoma. 3D-spoiled gradient recalled sequences were used for quantitative assessment of blood volume. The MRI-parameters were 5/22/35° (time of repetition (TR)/echo delay (TE)/flip angle (FA)) for T₁- and 50/61/10° for T₂-weighted sequences. Images were collected before and at different times after MION injection. In all untreated tissues studied, MION reduced the T₂-weighted signal intensity within 0.5 h and at 24 h (all p ≤ 0.012), whereas no significant changes were detected in treated tumors. T₁-weighted images also revealed differences of MION-related signal changes between treated tumors and other tissues, yet at lower sensitivity and specificity than T₂. The change of T₂-weighted MRI signal caused by intravascular MION allows early distinction of laser-treated experimental melanomas from untreated tissues. Further study is necessary to determine whether MRI can localize areas of tumor regrowth within tumors treated incompletely.
Uveal melanoma: Proton beam irradiation
2005, Ophthalmology Clinics of North America
How to Manage a Patient with Ocular Metastases?
2022, Biomedicines

View all citing articles on Scopus

: Presented at the American Academy of Ophthalmology Annual Meeting, Dallas, November 1992.

View full text